Analysts expect Alimera Sciences Inc (NASDAQ:ALIM) to post ($0.06) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Alimera Sciences’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.06). Alimera Sciences posted earnings per share of ($0.08) during the same quarter last year, which indicates a positive year-over-year growth rate of 25%. The business is scheduled to announce its next earnings results on Thursday, May 2nd.

On average, analysts expect that Alimera Sciences will report full-year earnings of ($0.14) per share for the current financial year, with EPS estimates ranging from ($0.14) to ($0.13). For the next financial year, analysts forecast that the company will post earnings of $0.02 per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Alimera Sciences.

ALIM has been the topic of a number of recent research reports. ValuEngine upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. HC Wainwright set a $2.00 target price on shares of Alimera Sciences and gave the company a “buy” rating in a research note on Wednesday, February 20th. Finally, Zacks Investment Research cut Alimera Sciences from a “hold” rating to a “sell” rating in a report on Thursday, February 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $2.44.

Shares of Alimera Sciences stock traded down $0.04 during midday trading on Thursday, hitting $0.92. The company had a trading volume of 84,064 shares, compared to its average volume of 100,849. The company has a market cap of $66.55 million, a price-to-earnings ratio of -3.17 and a beta of 2.22. Alimera Sciences has a 1-year low of $0.72 and a 1-year high of $1.21.

Institutional investors have recently made changes to their positions in the company. B. Riley Wealth Management Inc. raised its stake in shares of Alimera Sciences by 23.5% during the 4th quarter. B. Riley Wealth Management Inc. now owns 101,906 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 19,407 shares in the last quarter. Royce & Associates LP bought a new position in Alimera Sciences during the 3rd quarter worth $195,000. Knott David M increased its position in Alimera Sciences by 20.1% during the 4th quarter. Knott David M now owns 387,901 shares of the biopharmaceutical company’s stock worth $279,000 after buying an additional 65,001 shares during the period. B. Riley Financial Inc. acquired a new stake in shares of Alimera Sciences during the 3rd quarter worth $447,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Alimera Sciences by 27.7% during the 3rd quarter. Renaissance Technologies LLC now owns 732,790 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 158,790 shares in the last quarter. Institutional investors own 50.32% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Further Reading: Trading based on a resistance level

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.